Basic Information

Gene symbol BIRC5 Synonyms API4, EPR-1 Type of gene protein-coding
Description baculoviral IAP repeat containing 5

GTO ID GTC3976
Trial ID NCT03072134
Disease Brain Glioma
Altered gene BIRC5
Therapeutic/Target gene Therapeutic gene
TherapyDNA oncolytic virus
Treatment NSCLC CRAd-Survivin-pk7
Co-treatment Temozolomide
PhasePhase1
Recruitment statusCompleted
TitleNeural Stem Cell Oncolytic Adenoviral Virotherapy of Newly Diagnosed Malignant Glioma
Year2017
CountryUnited States
Company sponsorNorthwestern University
Other ID(s)STU00203933|5P50CA221747-05
Vector information
Vectoradenovirus
ConstructNSC-CRAd-Survivin-pk7
Vector typea first generation, replication-defective adenovirus serotype 5 (Ad5) vector
Regulatory elementsurvivin promoter
Viral genome modificationAn oncolytic adenovirus, CRAd-S-pk7, was engineered by incorporating a survivin promoter to drive the expression of the replicative essential E1A gene, and modifying the Ad5 fiber protein with the addition of a polylysine sequence (pk7).
Additional featurepk7

Clinical Result

Cohort1: dose level 1
Administration route intratumoral injection|intravenous infusion
Dosage 0.5E8 NSCs loading 6.25E10 vp
Pts 3
Age Adult, Older_Adult
Adverse reactions 0/3(All-cause mortality); 1/3(Vascular disorders)
References PMID: 34214495
Cohort2: dose level 2
Administration route intratumoral injection|intravenous infusion
Dosage 1.0E8 NSCs loading 1.25E11 vp
Pts 3
Age Adult, Older_Adult
Adverse reactions 0/3(All-cause mortality); 1/3(Nervous system disorders)
References PMID: 34214495
Cohort3: dose level 3
Administration route intratumoral injection|intravenous infusion
Dosage 1.5E8 NSCs loading 1.875E11 vp
Pts 6
Age Adult, Older_Adult
Adverse reactions 0/6(All-cause mortality); 1/3(Musculoskeletal and connective tissue disorders; Nervous system disorders)
References PMID: 34214495

Relationship Graph

Overview of Knowledge Graph